The Secret to Facial Rejuvenation

Play video

Instant Volume, Long-lasting benefits

When it comes to enhancing your appearance, you don’t want a quick fix. You want a safe* way to rejuvenate your skin, one that can elevate who you are and provide results that last. That’s where we come in... *Data on file

GET IN TOUCH

Rebuilding your natural beauty

Where others’ benefits end at correcting lines and folds, Ellansé goes beyond, goes deeper, working to treat the true causes of facial ageing. While it instantly addresses lines and wrinkles, it also uses your body’s natural processes to set in motion long-term collagen production, safely restoring volume, rejuvenating your appearance from within.

REQUEST A DEMO

The Secret to Facial rejuvenation

Ellansé goes beyond simply correcting superficial lines and folds. A unique dual-action dermal filler, it also works deep under the skin to treat the real causes of facial ageing by stimulating the body’s production of natural collagen.

MAKE AN ENQUIRY

We provide extensive training to create expert users and only work with the very best physicians in our industry. Ellansé offers a range of products to cover a variety of needs: from correcting wrinkles, to creating shape and volume. Its dual-action properties give patients both instant and long-lasting effects* whereby type one collagen is naturally stimulated. *Data on file.

SPEAK WITH OUR VIRTUAL ACCOUNT MANAGERS
We can create a more balanced face - a more desirable ratio between the features and its overall structure.

INDICATION:

The EU approved intended use is: Ellansé (a Poly-ɛ-caprolactone-based dermal filler) is an injectable implant, indicated for subdermal implantation in the face for the lasting correction of wrinkles and facial aging signs or conditions.

0344 Factory Industry Construction Symbol Company, PNG, 512x512px, Factory, Area, Black, Black And White, Brand Download Free W321.02. Manufactured by: AQTIS Medical BV, Yalelaan 44, 3584 CM Utrecht, The Netherlands.
CorWeb.03

Ellansé Summary of Safety and Clinical Performance

INDICATION:

The EU approved intended use is: Ellansé (a Poly-ɛ-caprolactone-based dermal filler) is an injectable implant, indicated for subdermal implantation in the face for the lasting correction of wrinkles and facial aging signs or conditions.

Important Safety Considerations:

Like all procedures of this type there is a possibility of adverse events, although not everybody experiences them. These adverse events include but are not limited to infection, minimal acute inflammatory tissue reaction (redness, swelling, rash, oedema, erythema, lumps/nodules etc.), pain (which may be temporary or persistent in nature), transient haematoma or bruising.

Other potential adverse events include

- Injection related reactions, include itching, discoloration or tenderness may occur at the site of the injection. These usually resolve spontaneously within several days after the injection.

- As with any implant material possible adverse reactions that may occur include, but are not limited to the following: hypersensitivity, allergic reactions, inflammation, infection, fistula formation, haematoma, seroma, extrusion, induration formation, inadequate healing, skin discoloration, oedema, contusions/bruises, ecchymosis, inadequate or excessive augmentation, loss of correction, interference with local circulation if injected into a blood vessel resulting in vessel laceration, occlusion, embolism, infarction, and abscess at implant site which may result in induration and/or scar formation.

- Rare but serious adverse events associated with the intravascular injection of soft tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral haemorrhage, leading to stroke, skin necrosis, damage to underlying facial structures, nausea and vomiting, lack of ocular movement, significant skin changes, ptosis, exotropia and neurological complications.

- Adverse events, other than mentioned above, could occur as can be with any medical intervention.

All (potential) adverse side effects and incidents should be reported immediately to the Sinclair Pharma Corporate Safety Group: quality@sinclairpharma.com